Health CarePharmaceuticals & Biotechnology
  • Price (SEK)61.40
  • Today's Change-1.10 / -1.76%
  • Shares traded87.19k
  • 1 Year change40.18%
  • Beta1.4104
Data delayed at least 15 minutes, as of Aug 20 2019 17:00 BST.
More ▼

Events & Activity

  • ORX:STO price moved over +2.17% to 61.30
  • ORX:STO trading volume exceeds daily average by +16.19%

Key statistics

On Tuesday, Orexo AB (ORX:STO) closed at 61.40, 56.23% above the 52 week low of 39.30 set on Sep 10, 2018.
52-week range
39.30Sep 10 201887.90Mar 25 2019
Markit short selling activity
Previous close62.50
Average volume94.47k
Shares outstanding34.71m
Free float31.18m
P/E (TTM)12.12
Market cap2.17bn SEK
EPS (TTM)5.15
Data delayed at least 15 minutes, as of Aug 20 2019 17:00 BST.
More ▼
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.